Table 2.
TLR10 expression in B cells and B cell subsets in the study subjects.
| Control (n = 30) | RA (n = 77) | P ∗ | LA (n = 19) | MA (n = 29) | HA (n = 29) | P # | |
|---|---|---|---|---|---|---|---|
| CD19+ | |||||||
| % | 51.4 ± 2.4 | 53.0 ± 1.7 | 0.612 | 43.8 ± 2.0 | 51.9 ± 2.5 | 60.2 ± 2.9 | 0.001 |
| MFI | 17.5 ± 0.4 | 17.5 ± 0.3 | 0.908 | 16.2 ± 0.2 | 17.1 ± 0.4 | 18.7 ± 0.6 | 0.03 |
| CD19+CD27+ | |||||||
| % | 73.3 ± 2.2 | 72.7 ± 1.6 | 0.829 | 67.1 ± 3.3 | 72.2 ± 7.4 | 76.8 ± 2.6 | 0.038 |
| MFI | 22.7 ± 1.0 | 22.8 ± 0.6 | 0.932 | 20.8 ± 0.7 | 21.8 ± 0.7 | 25.1 ± 1.3 | 0.093 |
| CD19+CD27− | |||||||
| % | 43.7 ± 2.4 | 46.5 ± 1.8 | 0.385 | 36.8 ± 2.4 | 45.2 ± 2.3 | 54.2 ± 3.2 | 0.001 |
| MFI | 15.4 ± 0.3 | 15.9 ± 0.2 | 0.207 | 20.8 ± 0.7 | 15.6 ± 0.3 | 16.9 ± 0.5 | ≤0.001 |
| CD19+CD27+IgD− | |||||||
| % | 78.3 (60.6-83.5) | 74.5 (61.5-84.3) | 0.914 | 62.1 (58.6-78.8) | 74.8 (62.0-80.8) | 80.1 (65.3-87.3) | 0.054 |
| FI | 22.5 (19.0-25.1) | 21.9 (19.5-25.0) | 0.819 | 20.4 (18.4-22.9) | 21.7 (19.2-25.2) | 22.1 (20.2-31.1) | 0.097 |
| CD19+CD27+IgD+ | |||||||
| % | 72.3 (55.8-81.4) | 72.2 (61.0-84.6) | 0.479 | 70.0 (53.9-78.3) | 69.4 (57.8-83.5) | 77.6 (67.8-88.5) | 0.026 |
| FI | 18.8 (17.5-22.6) | 20.6 (17.9-24.2) | 0.276 | 18.3 (16.4-22.1) | 19.8 (18.1-25.8) | 21.9 (18.5-26.1) | 0.101 |
| CD19+CD27−IgD+ | |||||||
| % | 43.8 (33.9-55.0) | 43.4 (35.1-55.4) | 0.737 | 38.9 (28.2-41.9) | 43.5 (37.5-53.1) | 54.4 (38.9-68.6) | 0.001 |
| FI | 15.4 (14.1-16.4) | 15.0 (13.9-16.4) | 0.605 | 14.1 (13.8-14.6) | 15.5 (14.0-15.9) | 15.7 (14.6-18.1) | 0.002 |
| CD19+CD27−IgD− | |||||||
| % | 40.5 (26.4-49.8) | 42.8 (35.0-62.2) | 0.047 | 36.7 (26.1-46.4) | 41.6 (33.5-61.8) | 54.5 (39.0-67.9) | 0.016 |
| MFI | 16.7 (15.0-18.3) | 17.0 (15.3-20.4) | 0.167 | 16.3 (15.3-17.2) | 18.1 (15.1-20.7) | 18.3 (15.7-21.7) | 0.126 |
| CD19+CD5+ | |||||||
| % | 34.6 (25.7-46.8) | 44.3 (33.2-54.0) | 0.024 | 36.0 (30.5-44.2) | 44.3 (32.6-52.8) | 52.0 (42.7-68.0) | 0.002 |
| MFI | 16.1 (14.1-17.0) | 16.1 (14.6-17.5) | 0.397 | 14.6 (14.2-16.8) | 16.4 (15.2-17.3) | 16.5 (15.0-18.6) | 0.034 |
| CD19+CD5− | |||||||
| % | 52.1 (36.2-63.4) | 45.0 (34.9-59.0) | 0.435 | 41.1 (35.0-45.4) | 41.9 (30.7-58.2) | 51.7 (39.4-67.6) | 0.033 |
| MFI | 16.9 (15.5-19.0) | 16.5 (15.3-18.5) | 0.304 | 15.8 (15.0-17.2) | 15.8 (15.0-19.0) | 16.8 (15.8-18.9) | 0.098 |
The data are shown as the means ± SE or median (interquartile range, 25th-75th). ∗ represents a comparison between the RA subjects and HCs based on the Mann–Whitney test. # represents a comparison among the three groups of RA subjects based on the Kruskal–Wallis test.